Advertisement
News
Subscribe to MDT Magazine News

NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group

September 8, 2010 7:31 am | by Bio-Medicine.Org | Comments

POWAY, Calif., Sept. 8 /- NEXUS Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, today announced the completion of the acquisition of REMP AG of Switzerland, a wholly-owned subsidiary of the Tecan Group.   NEXUS announced on July...

TOPICS:

Misonix Announces New Distribution Agreement for France

September 8, 2010 6:32 am | by Bio-Medicine.Org | Comments

FARMINGDALE, N.Y., Sept. 8 /- Misonix, Inc. (Nasdaq: MSON ), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, three year, exclusive distribution agreement with Cormedica s.a.s.  Based...

TOPICS:

Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology

September 8, 2010 6:31 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Sept. 7 /- GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology . Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by...

TOPICS:
Advertisement

Researchers Explore Use for Head, Neck, Prostate, Breast and Lung Tumors, as Well as More Complex Blood Cancer and Mesothelioma Treatments

September 8, 2010 5:45 am | by The Associated Press | Comments

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that 82 studies examining the use of the TomoTherapy@ treatment system to treat common, complex and rare tumors...

electronica 2010 ? electronics industry demonstrates its future viability

September 8, 2010 5:33 am | by I-Micronews | Comments

electronica will present the future of the electronics industry at the New Munich Trade Fair Center from November 9 to 12, 2010.

Cardiorobotics collects $500K of planned $5M round

September 8, 2010 5:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Less than one year after raising a $5 million funding round, Cardiorobotics Inc. has started another $5 million round with a $500,000 tranche.

Diabetes-focused biotech Rhythm closes $40M Series A round

September 8, 2010 5:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Rhythm Pharmaceuticals Inc., a startup focused on obesity and diabetes treatments, had closed a $40 million Series A financing, funded by MPM Capital and Third Rock Ventures, both of Boston, as well as New Enterprise Associates of Maryland.

Streamline Health Document Workflow Solutions Purchased By Tampa, Florida-Based Hospital

September 8, 2010 3:33 am | by Bio-Medicine.Org | Comments

CINCINNATI, Sept. 8 /- Streamline Health Solutions, Inc. (Nasdaq: STRM ) a leading provider of document workflow solutions for hospitals, today announced that a leading Tampa, Florida-based medical institution has purchased three additional workflow licenses to expand the use of...

TOPICS:
Advertisement

STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS

September 8, 2010 3:33 am | by Bio-Medicine.Org | Comments

MONROVIA, Calif., Sept. 8 /- STAAR Surgical Company (Nasdaq: STAA ), the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by...

TOPICS:

MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program

September 8, 2010 3:33 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Sept. 8 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed...

TOPICS:

Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference

September 8, 2010 3:33 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., Sept. 8 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at Stifel Nicolaus' 2010 Healthcare Conference on Thursday, September 16, 2010 at 8:35 a.m. ET at The Four Seasons...

TOPICS:

MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial

September 8, 2010 3:33 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Sept. 8 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX™, dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo....

TOPICS:

N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor

September 8, 2010 3:33 am | by Bio-Medicine.Org | Comments

BOULDER, Colo., Sept. 8 /- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be...

TOPICS:

Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online

September 8, 2010 3:32 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., Sept. 8 /- Cardiogenesis Corporation (OTCQB: CGCP) today announced that the Wall Street Reporter has interviewed Cardiogenesis' Executive Chairman Paul J. McCormick.  The interview includes a discussion of the Company's results for the first half of 2010, including an...

TOPICS:

Abbott Completes Acquisition of Piramal's Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India

September 8, 2010 1:32 am | by Bio-Medicine.Org | Comments

India's rapid pharmaceutical market growth is being driven largely by branded generics. The market will generate nearly $8 billion in pharmaceutical sales this year, a number that is expected to more than double by 2015. Abbott expects its pharmaceutical sales in India to exceed $2.5...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading